[Ip-health] KEI Briefing Note 2016:2: 2015-2016 Pharmaceutical Transparency Legislation

Zack Struver zack.struver at keionline.org
Tue Sep 6 10:11:05 PDT 2016

The attached briefing note (
analyzes transparency legislation that has been proposed in 14 states in
2015 and 2016. The bills would require various degrees of transparency for
research and development (R&D) and marketing costs, as well as for drug
prices and price changes.

The executive summary is reproduced below:

*20 bills introduced in 14 states in 2015 and 2016 would enact varying
degrees of transparency in the pharmaceutical sector for various costs
associated with research and development (R&D) and marketing, and for

*18 bills would require disclosure of costs associated with R&D, marketing
and advertising, and manufacturing.

*19 bills would require disclosure of average wholesale price (AWP) or
wholesale acquisition cost (WAC), or both.

*4 bills would require the implementation of cost control measures for
high­priced drugs or drugs that adversely affect state health care budgets.

*Overall, 11 of the 20 bills could be traced to 4 originator bills. One of
the 20 bills became law in 2016.

The briefing note may be cited as KEI Briefing Note 2016:2, "2015­-2016
Pharmaceutical Transparency Legislation," September 2016, DOI:

Zack Struver, Communications and Research Associate
Knowledge Ecology International
zack.struver at keionline.org
Twitter: @zstruver <https://twitter.com/zstruver>
Office: +1 (202) 332-2670 Cell: +1 (914) 582-1428

More information about the Ip-health mailing list